

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicant:	Ashley, Robert	Examiner:	Susan Tran
Serial No.:	13/277,789	Group Art Unit:	1615
Confirmation No:	4179	Docket:	512-53 DIV/CON II
Filed:	October 20, 2011	Dated:	September 19, 2012
For:	<b>Methods of Treating Acne</b>		

Commissioner for Patents  
P.O. Box 1450  
Alexandria, Virginia 22313-1450

**Certificate of EFS-Web Transmission**

I hereby certify that this correspondence is being transmitted to the United States Patent and Trademark Office via the Office's electronic filing system on September 19, 2012

Printed Name: Carla Bryan

Signature: /carla bryan/

**Response to May 14, 2012 Office Action**

Sir:

In Response to May 14, 2012 Office Action, Applicant respectfully requests the instant Amendment be entered.

**Amendments to the Claims** begin on page 2 of this paper.

**Remarks** begin on page 5 of this paper.

Dr. Reddy's Laboratories, Ltd., et al. v. Galderma Laboratories, Inc. IPR2015-_____
--

**Listing of the Claims:**

*This listing of claims will replace all prior versions, and listings, of claims in the application.*

Claims 1-20 (Cancelled).

21. (Previously Presented) A method for treating papules and pustules of rosacea in a human in need thereof, the method comprising
- administering orally to said human doxycycline, or a pharmaceutically acceptable salt thereof,
  - in an amount that
  - (i) is effective to treat the papules and pustules of rosacea;
  - (ii) is 10-80% of a 50 mg dose of doxycycline; and
  - (iii) results in no reduction of skin microflora during a six-month treatment, without administering a bisphosphonate compound.
22. (Previously Presented) The method according to Claim 21, wherein said doxycycline is doxycycline monohydrate.
23. (Previously Presented) The method according to Claim 22, wherein said doxycycline monohydrate is administered in an amount of 40 milligrams.
24. (Previously Presented) The method according to Claim 23, wherein said doxycycline monohydrate is administered by sustained release.
25. (Previously Presented) A method according to Claim 24, wherein said doxycycline monohydrate is administered once a day.
26. (Previously Presented) The method according to Claim 22, wherein said doxycycline monohydrate is administered in a dose of 20 mg twice a day.

27. (Previously Presented) The method according to Claim 21, wherein said doxycycline, or a pharmaceutically acceptable salt thereof, is administered in an amount which provides a serum concentration in the range of about 0.1 to about 0.8 µg/ml.

28. (Previously Presented) A method for treating papules and pustules of rosacea in a human in need thereof, the method comprising  
administering orally to said human doxycycline, or a pharmaceutically acceptable salt thereof,  
in an amount that  
(i) is effective to treat the papules and pustules of rosacea;  
(ii) is 40-80% of a 50 mg dose of doxycycline; and  
(iii) results in no reduction of skin microflora during a six-month treatment, without administering a bisphosphonate compound.

29. (Previously Presented) The method according to Claim 28, wherein said doxycycline is doxycycline monohydrate.

30. (Previously Presented) The method according to Claim 29, wherein said doxycycline monohydrate is administered in an amount of 40 milligrams.

31. (Previously Presented) The method according to Claim 30, wherein said doxycycline monohydrate is administered by sustained release.

32. (Previously Presented) A method according to Claim 31, wherein said doxycycline monohydrate is administered once a day.

33. (Previously Presented) The method according to Claim 29, wherein said doxycycline monohydrate is administered in a dose of 20 mg twice a day.

34. (Previously Presented) The method according to Claim 28, wherein said doxycycline, or a pharmaceutically acceptable salt thereof, is administered in an amount which provides a serum concentration in the range of about 0.1 to about 0.8  $\mu\text{g/ml}$ .

35. (Previously Presented) A method for treating papules and pustules of rosacea in a human in need thereof, the method comprising  
administering orally to said human doxycycline, or a pharmaceutically acceptable salt thereof, in an amount of 40mg per day, wherein the amount results in no reduction of skin microflora during a six-month treatment, without administering a bisphosphonate compound.

36. (Previously Presented) The method according to Claim 35, wherein said doxycycline is doxycycline monohydrate.

37. (Previously Presented) The method according to Claim 36, wherein said doxycycline monohydrate is administered by sustained release.

38. (Previously Presented) A method according to Claim 37, wherein said doxycycline monohydrate is administered once a day.

39. (Previously Presented) The method according to Claim 36, wherein said doxycycline monohydrate is administered in a dose of 20 mg twice a day.

40. (Previously Presented) The method according to Claim 35, wherein said doxycycline, or a pharmaceutically acceptable salt thereof, is administered in an amount which provides a serum concentration in the range of about 0.1 to about 0.8  $\mu\text{g/ml}$ .

### **REMARKS**

Claims 1-20 were previously cancelled. Claims 21-40 were previously added. Thus, Claims 21-40 are pending.

### **The Claimed Invention**

Pending Claims 21, 28 and 35 are independent. These claims recite a method for treating papules and pustules of rosacea by oral administration of doxycycline (or a salt thereof). Papules and pustules occur on skin in facial rosacea. The dose is expressed differently in each independent claim. The dose recited in Claim 21 is 10-80% of a 50 mg dose of doxycycline. The dose recited in Claim 28 is 40-80% of a 50 mg dose of doxycycline. The dose recited in Claim 35 is 40 mg. The claims recite that all these doses result in no reduction of skin microflora during a six-month treatment

Applicant takes this opportunity to elaborate on the disease of rosacea. There are four sub-types of rosacea. Rosacea patients can have any one, or occasionally more than one, of these sub-types. One sub-type affects the eyes and is called ocular rosacea. Another sub-type is characterized by papules and pustules, and is called herein facial rosacea.<sup>1</sup> Ocular rosacea and facial rosacea are distinct medical conditions.<sup>2</sup>

---

<sup>1</sup> The National Rosacea Society assembled a committee to develop a standard classification system of rosacea. Their report, authored by Wilkin et al., appeared in *J. Am. Acad. Dermatol.* 46, 584-587 (2002), and is attached as Exhibit A. This authoritative report identified four specific sub-types of rosacea. Subtype 2 is called "papulopustular rosacea," and is characterized by transient papules and/or pustules. Subtype 4 is called "ocular rosacea," and is characterized by ocular manifestations.

<sup>2</sup> (a) In addition to evidence provided in footnote 1, facial rosacea and ocular rosacea are treated by physicians in different specialties with different Board certifications, *i.e.*, dermatologists and ophthalmologists, respectively.

(b) Moreover, the agency that approves drugs in the United States, namely the Center for Drug Evaluation and Research (CDER) of the Food and Drug Administration, evaluates drugs for facial rosacea and ocular rosacea in different divisions. Facial rosacea is evaluated in the Division of Dermatologic and Dental Products. Ocular rosacea is evaluated in the Division of Anti-Infection and Ophthalmologic Products. For the examiner's convenience, a 2006 chart of the organization of the CDER showing the separate divisions of Dermatologic and Dental Products and of Anti-Infection and Ophthalmologic Products is attached as Exhibit B.

# Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

## Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

## Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

## API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

## LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

## FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

## E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.